Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Yekeduz, Emre; ÖZBAY, MEHMET; Caglayan, Dilek; YILDIRIM, ATİLA; Erol, Cihan; YILDIRIM, HASAN; Tunc, Sezai; Ozyurt, Neslihan; ÖZDEMİR, FEYYAZ; ŞENDUR, MEHMET; Isikdogan, Abdurrahman; Kilickap, Saadettin; Urun, Yuksel; Yalcin, Suayib; Artac, Mehmet; Coskun, Hasan; Utkan, Gungor

doi:10.1007/s00228-022-03403-1

Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Yekeduz E., ÖZBAY M. F., Caglayan D., YILDIRIM A., Erol C., YILDIRIM H. Ç., ...More

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.78, no.12, pp.1973-1979, 2022 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 78 Issue: 12
Publication Date: 2022
Doi Number: 10.1007/s00228-022-03403-1
Journal Name: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, Chimica, CINAHL, EMBASE, MEDLINE
Page Numbers: pp.1973-1979
Keywords: Drug-drug interactions, Acid suppression, Regorafenib, TYROSINE-KINASE INHIBITORS, DRUG-DRUG INTERACTIONS, SOLID TUMORS, TRANSPORTERS, RESISTANCE, THERAPY
Open Archive Collection: AVESIS Open Access Collection
Karadeniz Technical University Affiliated: Yes

Abstract

Aim To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and nonuser patients with metastatic colorectal cancer (mCRC) treated with regorafenib.